Literature DB >> 9935202

Aberrant expression of MUC5AC and MUC6 gastric mucin genes in colorectal polyps.

A E Bartman1, S J Sanderson, S L Ewing, G A Niehans, C L Wiehr, M K Evans, S B Ho.   

Abstract

Altered mucin glycosylation and the de novo appearance of gastric mucin antigens have been described in colonic adenomas. The purpose of our study was to determine if expression of the gastric mucin genes MUC5AC and MUC6 occurs in colorectal adenomas and whether this correlates with histopathologic criteria of malignant potential. Immunohistochemical staining using antibodies against MUC5AC and MUC6 tandem repeat synthetic peptides was performed on specimens of normal colon mucosa (n = 26), hyperplastic polyps (n = 9) and adenomatous polyps (n = 111). Mucin mRNA levels were determined using RNase protection assays using riboprobes corresponding to unique non-repetitive sequences. MUC5AC and MUC6 staining were rarely detected and of low intensity in normal colon and hyperplastic polyps. The number of immunoreactive polyps and intensity of MUC5AC and MUC6 staining were greatest in larger adenomas of moderate villous histology and dysplasia. MUC5AC and MUC6 staining tended to decrease in highly villous polyps with severe dysplasia. Increased MUC5AC mRNA levels were found in 26/45 of adenomas tested compared with 0/9 normal colon specimens. MUC6 mRNA levels were found in 20/45 of adenomas compared with 1/9 normal colon specimens. MUC5AC and MUC6 mRNA were present more frequently and at higher levels in polyps with intermediate stages of size, villous histology and dysplasia. We conclude that aberrant expression of MUC5AC and MUC6 mucin genes is likely responsible for an expanded repertoire of mucin antigen expression in colorectal neoplasia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9935202     DOI: 10.1002/(sici)1097-0215(19990118)80:2<210::aid-ijc9>3.0.co;2-u

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  40 in total

Review 1.  Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease.

Authors:  A P Corfield; N Myerscough; R Longman; P Sylvester; S Arul; M Pignatelli
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

2.  Glycosylation of human fetal mucins: a similar repertoire of O-glycans along the intestinal tract.

Authors:  Catherine Robbe-Masselot; Emmanuel Maes; Monique Rousset; Jean-Claude Michalski; Calliope Capon
Journal:  Glycoconj J       Date:  2008-09-20       Impact factor: 2.916

3.  Poorly differentiated adenocarcinoma of the colon: subsite location and clinicopathologic features.

Authors:  Yasuo Imai
Journal:  Int J Colorectal Dis       Date:  2014-11-23       Impact factor: 2.571

4.  Association of MUC6-minisatellite variants with susceptibility to rectal carcinoma.

Authors:  Myoung-Hyun Ahn; Ki Beom Bae; Jeong-Ah Kwon; Hong-Jo Choi; Se-Ra Lee; Si-Hoon Kim; Tae Doo Jung; Sun Hee Kim; Min Sung An; Kwan Hee Hong; Jeonghoon Heo; Tae-Hong Kang; Jin Woong Chung; Sun-Hee Leem
Journal:  Mol Biol Rep       Date:  2012-10-10       Impact factor: 2.316

5.  Altered mucin core peptide expression in acute and chronic cholecystitis.

Authors:  S B Ho; L L Shekels; N W Toribara; I K Gipson; Y S Kim; P P Purdum; D L Cherwitz
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

6.  Mucin gene expression in the ileoanal reservoir is altered and may be relevant to the risk of inflammation and dysplasia.

Authors:  P A Sylvester; M Walsh; N Myerscough; B F Warren; A P Corfield; M G Thomas; P Durdey
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 7.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

8.  Mucins in neoplastic spectrum of colorectal polyps: can they provide predictions?

Authors:  Mahsa Molaei; Babak Khoshkrood Mansoori; Reza Mashayekhi; Mohsen Vahedi; Mohamad Amin Pourhoseingholi; Seyed Reza Fatemi; Mohammad Reza Zali
Journal:  BMC Cancer       Date:  2010-10-07       Impact factor: 4.430

9.  A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.

Authors:  Muhammad S Beg; Nilofer S Azad; Sandip P Patel; Jose Torrealba; Sharon Mavroukakis; Melony A Beatson; Xue Ping Wang; Philip M Arlen; Michael A Morse
Journal:  Cancer Chemother Pharmacol       Date:  2016-07-23       Impact factor: 3.333

10.  Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps.

Authors:  Angela N Bartley; Patricia A Thompson; Julie A Buckmeier; Carole Y Kepler; Chiu-Hsieh Hsu; Manuel S Snyder; Peter Lance; Achyut Bhattacharyya; Stanley R Hamilton
Journal:  Mod Pathol       Date:  2009-10-23       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.